ArticleDiscover oncology2025
Elevated NUF2 and CD52 expression predict platinum-based chemoresistance and poor prognosis in non-small cell lung cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to explore the clinical significance of the cytokinesis-associated gene NUF2 and the immune-related gene CD52 in non-small cell lung cancer (NSCLC), with a focus on their association with platinum-based chemoresistance and patient prognosis.
methodsCancer and matched adjacent non-tumorous tissues were obtained from 72 NSCLC patients who underwent surgical resection. Immunohistochemical (IHC) staining was performed to assess the expression of NUF2 and CD52. Patients were stratified based on combined staining intensity and extent scores. All patients received gemcitabine plus cisplatin chemotherapy. Associations between gene expression and chemotherapy response, clinicopathological features, and overall survival were evaluated. Kaplan-Meier survival analysis and Cox regression modeling were used to identify independent prognostic factors.
resultsNUF2 and CD52 showed significantly higher expression in NSCLC tissues compared to adjacent controls (66.67% and 62.50% positivity, respectively; P < 0.05). Positive expression of both genes was significantly associated with advanced TNM stage, poor differentiation, lymph node metastasis, pleural invasion, and vascular thrombus formation (P < 0.05). Post-chemotherapy non-remission rates were significantly elevated in NUF2- and CD52-positive patients (P < 0.05). Kaplan-Meier analysis revealed markedly reduced median survival in patients with positive NUF2 and CD52 expression (P < 0.05). Multivariate Cox analysis identified platinum resistance, lymph node metastasis, pleural invasion, and positive expression of NUF2 and CD52 as independent predictors of poor prognosis.
conclusionHigh expression of NUF2 and CD52 is closely linked to platinum resistance and aggressive tumor behavior in NSCLC, and serves as an independent predictor of adverse outcomes. These markers may hold potential as prognostic indicators and therapeutic targets in chemoresistant NSCLC. These findings, while promising, are based on a single-center retrospective cohort and should be validated in larger, independent studies to confirm their clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.